News
GOSS
--
0.00%
--
Have Insiders Been Buying Gossamer Bio, Inc. (NASDAQ:GOSS) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Simply Wall St. · 1d ago
Is GOSS A Good Stock To Buy Now According To Hedge Funds?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bou...
Insider Monkey · 12/19/2020 20:54
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 14, 2020: MRNA, LEN, WISH, RMG, GOSS
Today's 5 Stock Ideas:  Moderna (MRNA) - Shares traded higher with the broader stock market following news late Friday COVID-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) received
Benzinga · 12/14/2020 13:31
The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics
Biotech stocks advanced for a third straight week, defying the broader market weakness. The space got solid support from positive stock reactions to presentations made at hematology and breast cancer conferences.
Benzinga · 12/13/2020 14:14
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.
GlobeNewswire · 12/11/2020 23:40
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 12/11/2020 20:30
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
Business Wire · 12/07/2020 12:03
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
Business Wire · 12/07/2020 12:03
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that the Company’s Board of Directors has appointed Faheem Hasnain as Chief Executive Officer and President, effective immediately. Mr. Hasnain is a Co-Founder, former Chief Executive Officer, and current Chairman of Gossamer Bio. Mr. Hasnain succeeds Sheila Gujrathi, M.D., a Co-Founder of Gossamer Bio, who served as Chief Executive Officer and President since July 2018. Dr. Gujrathi will continue in an advisory role to the Company.
Business Wire · 11/16/2020 12:01
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
Business Wire · 11/16/2020 12:01
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial result...
Business Wire · 11/10/2020 21:01
Gossamer Bio, Inc. to Host Earnings Call
ACCESSWIRE · 11/10/2020 19:30
Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update
* Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021 * Initiated second clinical trial to evaluate razuprotafib for the prevention and treatment o...
GlobeNewswire · 11/10/2020 13:00
Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020
Business Wire · 11/06/2020 12:07
Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present...
Business Wire · 11/06/2020 12:03
Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome ("ARDS") associated with COVID-19 infections, will release its financial results for the third quarter ended September 30, 2020, before the market open on Tuesday, November 10, 2020, and host a webcast and conference call at 8:30am ET.
GlobeNewswire · 11/05/2020 21:03
Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19
Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome ("ARDS") associated with COVID-19 infections, announced that it will host a key opinion leader (KOL) call on new therapeutic agents for the treatment of COVID-19 on Thursday, November 12, 2020 at 11am Eastern Time.
GlobeNewswire · 11/05/2020 21:03
Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19
Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activ...
GlobeNewswire · 11/05/2020 21:03
Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that acti...
GlobeNewswire · 11/05/2020 21:03
Webull provides a variety of real-time GOSS stock news. You can receive the latest news about Gossamer Bio through multiple platforms. This information may help you make smarter investment decisions.
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
More